 Carcinoma, Non-Small-Cell Lung
"Carcinoma, Non-Small-Cell Lung" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.
| Descriptor ID |
D002289
|
| MeSH Number(s) |
C04.588.894.797.520.109.220.249 C08.381.540.140.500 C08.785.520.100.220.500
|
| Concept/Terms |
Carcinoma, Non-Small-Cell Lung- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Non Small Cell Lung
- Carcinomas, Non-Small-Cell Lung
- Lung Carcinoma, Non-Small-Cell
- Lung Carcinomas, Non-Small-Cell
- Non-Small-Cell Lung Carcinomas
- Non-Small Cell Lung Cancer
- Non-Small-Cell Lung Carcinoma
- Non Small Cell Lung Carcinoma
- Carcinoma, Non-Small Cell Lung
|
Below are MeSH descriptors whose meaning is more general than "Carcinoma, Non-Small-Cell Lung".
Below are MeSH descriptors whose meaning is more specific than "Carcinoma, Non-Small-Cell Lung".
This graph shows the total number of publications written about "Carcinoma, Non-Small-Cell Lung" by people in this website by year, and whether "Carcinoma, Non-Small-Cell Lung" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1986 | 1 | 0 | 1 | | 1987 | 2 | 0 | 2 | | 1989 | 3 | 1 | 4 | | 1990 | 4 | 2 | 6 | | 1991 | 1 | 1 | 2 | | 1992 | 3 | 0 | 3 | | 1993 | 6 | 0 | 6 | | 1994 | 6 | 3 | 9 | | 1995 | 7 | 2 | 9 | | 1996 | 4 | 0 | 4 | | 1997 | 4 | 0 | 4 | | 1998 | 10 | 1 | 11 | | 1999 | 4 | 0 | 4 | | 2000 | 5 | 2 | 7 | | 2001 | 7 | 2 | 9 | | 2002 | 6 | 1 | 7 | | 2003 | 17 | 1 | 18 | | 2004 | 8 | 1 | 9 | | 2005 | 13 | 5 | 18 | | 2006 | 14 | 4 | 18 | | 2007 | 19 | 2 | 21 | | 2008 | 18 | 4 | 22 | | 2009 | 16 | 3 | 19 | | 2010 | 20 | 3 | 23 | | 2011 | 38 | 4 | 42 | | 2012 | 27 | 0 | 27 | | 2013 | 32 | 1 | 33 | | 2014 | 21 | 3 | 24 | | 2015 | 45 | 2 | 47 | | 2016 | 38 | 4 | 42 | | 2017 | 29 | 2 | 31 | | 2018 | 43 | 4 | 47 | | 2019 | 41 | 3 | 44 | | 2020 | 50 | 2 | 52 | | 2021 | 45 | 3 | 48 | | 2022 | 13 | 0 | 13 |
To return to the timeline, click here.
Below are the most recent publications written about "Carcinoma, Non-Small-Cell Lung" by people in Profiles.
-
Boucai L, Salas-Lucia F, Krishnamoorthy GP, Sherman E, Rudin CM, Drilon A, Bianco AC, Fagin JA. Selpercatinib-Induced Hypothyroidism Through Off-Target Inhibition of Type 2 Iodothyronine Deiodinase. JCO Precis Oncol. 2022 Jun; 6:e2100496.
-
Schild SE, Wang X, Bestvina CM, Williams T, Masters G, Singh AK, Stinchcombe TE, Salama JK, Wolf S, Zemla T, Duma N, Chun SG, Amini A, Kozono D, Watt C. Alliance A082002 -a randomized phase II/III trial of modern immunotherapy-based systemic therapy with or without SBRT for PD-L1-negative, advanced non-small cell lung cancer. Clin Lung Cancer. 2022 Jul; 23(5):e317-e320.
-
Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, Felip E, Broderick SR, Brahmer JR, Swanson SJ, Kerr K, Wang C, Ciuleanu TE, Saylors GB, Tanaka F, Ito H, Chen KN, Liberman M, Vokes EE, Taube JM, Dorange C, Cai J, Fiore J, Jarkowski A, Balli D, Sausen M, Pandya D, Calvet CY, Girard N. Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. N Engl J Med. 2022 05 26; 386(21):1973-1985.
-
Strohbehn GW, Ratain MJ. Lorlatinib Exposed: A Far From Optimal Dose. Clin Pharmacol Ther. 2022 Jun; 111(6):1195-1196.
-
Chhatre S, Murgu S, Vachani A, Jayadevappa R. Photodynamic therapy for stage I and II non-small cell lung cancer: A SEER-Medicare analysis 2000-2016. Medicine (Baltimore). 2022 Mar 18; 101(11).
-
Le X, Sakai H, Felip E, Veillon R, Garassino MC, Raskin J, Cortot AB, Viteri S, Mazieres J, Smit EF, Thomas M, Iams WT, Cho BC, Kim HR, Yang JC, Chen YM, Patel JD, Bestvina CM, Park K, Griesinger F, Johnson M, Gottfried M, Britschgi C, Heymach J, Sikoglu E, Berghoff K, Schumacher KM, Bruns R, Otto G, Paik PK. Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice. Clin Cancer Res. 2022 03 15; 28(6):1117-1126.
-
Ferrara R, Milani M, Garassino MC, Colombo MP, Sangaletti S. Adenosine Pathway in NSCLC With Molecular Drivers: Can Oncogene Addiction Translate Into Immune Addiction? J Thorac Oncol. 2022 03; 17(3):e35-e38.
-
Lee JK, Hazar-Rethinam M, Decker B, Gjoerup O, Madison RW, Lieber DS, Chung JH, Schrock AB, Creeden J, Venstrom J, Alexander B, Oxnard GR. The Pan-Tumor Landscape of Targetable Kinase Fusions in Circulating Tumor DNA. Clin Cancer Res. 2022 02 15; 28(4):728-737.
-
Spigel DR, Faivre-Finn C, Gray JE, Vicente D, Planchard D, Paz-Ares L, Vansteenkiste JF, Garassino MC, Hui R, Quantin X, Rimner A, Wu YL, Özgüroglu M, Lee KH, Kato T, de Wit M, Kurata T, Reck M, Cho BC, Senan S, Naidoo J, Mann H, Newton M, Thiyagarajah P, Antonia SJ. Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. J Clin Oncol. 2022 04 20; 40(12):1301-1311.
-
Liu J, Bratton E, Yu X, Ladbury C, Wagner J, West H, Massarelli E, Salgia R, Pathak R, Villaflor V, Villalona-Calero M, Amini A. Patterns of Care in Maintenance Therapy in US Patients Undergoing Definitive Chemoradiation for Stage 3 Non-Small Cell Lung Cancer (NSCLC). Am J Clin Oncol. 2022 02 01; 45(2):49-54.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|